Session 3: New Drug Discovery & Development in HIV & Serious Epidemic Infectious Diseases
|
|
Title: Blocking Viral Entry: A Complementary Strategy for HIV Therapy
Dr. Shibo Jiang, Head of Viral Immunology Laboratory, New York Blood Center, USA
|
|
Title: The Importance of Very Early Detection of HIV for Both Vaccine Trials and Antiretroviral Drug Treatment
Dr. Miles Cloyd , Professor£¬Univ. of Texas Medical Branch
|
|
Title: Limitations of Current HIV/DNA Vaccines
Dr. Dinesh K. Singh , Assistant Professor, Winston Salem State University, USA
|
|
Title: Sifuvirtide, an HIV Fusion Inhibitor
Dr. Jason Genfa Zhou , Chairman, FusoGen Pharmaceuticals, Inc., China
|
|
Title: Mechanism of Anti-Human Immunodeficiency Virus Activity of b -D-6-Cyclopropylamino-2',3'-Didehydro-2',3'-Dideoxyguanosine
Dr. Zhenjun Yang, Associate Professor, School of Pharmaceutical Sciences, Peking University Health Science Center, China
|
|
Title: Discovery of AN-2690, a Clinical NCE For Topical Onychomycosis Treatment
Dr. Yong-Kang Zhang , Senior Research Scientist, Medicinal Chemistry Department, Anacor Pharmaceuticals, Inc.
|
|
Title: Naturally-occurring anti-HIV molecules
Dr. Daisuke Uemura , Professor, Nagoya University, Japan |
|
Title: Pharmacology limitations of current HIV therapies
Dr. Mario Regazzi , Head of Clinical PK and Drug TDM Laboratory, Dept. of Pharmacology, Italy
|
|
Home
